Christine A. Poon - 02 Nov 2026 Form 4 Insider Report for REGENERON PHARMACEUTICALS, INC. (REGN)

Reporting relationship: Director
Issuer ticker: REGN
Reported as of: 02 Nov 2026
Net transaction value: -$7,587,958
SEC form: 4
Accepted by SEC: 04 Nov 2026, 16:09:48 UTC
Prior SEC filing: 14 Sep 2026
Source filing: View source filing
Reporting owner signature: /s/ Christine A. Poon

Filing notes and source

Key filing fact

Christine A. Poon filed Form 4 for REGENERON PHARMACEUTICALS, INC. (REGN) on 04 Nov 2026.

Key facts

This page summarizes Christine A. Poon's Form 4 filing for REGENERON PHARMACEUTICALS, INC. (REGN).
8 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 04 Nov 2026, 16:09.

Change

Previous filing in this sequence was filed on 14 Sep 2026.
Current net transaction value: -$7,587,958.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001189014 Primary reporting owner

POON CHRISTINE A

Relationship: Director
Address: 777 OLD SAW MILL RIVER ROAD, TARRYTOWN
Signature: /s/ Christine A. Poon
Signature date: 04 Nov 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

REGN transaction

Common Stock

Options Exercise

Transaction value
Shares: +7,830
Change %: +150%
Price: $376.69^*
Shares after: 13,049
Date: 02 Nov 2026
Ownership: Direct

REGN transaction

Common Stock

Sale

Transaction value: -$210,749
Shares: -218
Change %: -1.7%
Price: $966.74
Shares after: 12,831
Date: 02 Nov 2026
Ownership: Direct
Footnotes: F1

REGN transaction

Common Stock

Sale

Transaction value: -$746,817
Shares: -772
Change %: -6%
Price: $967.38
Shares after: 12,059
Date: 02 Nov 2026
Ownership: Direct
Footnotes: F2

REGN transaction

Common Stock

Sale

Transaction value: -$2,420,481
Shares: -2,499
Change %: -21%
Price: $968.58
Shares after: 9,560
Date: 02 Nov 2026
Ownership: Direct
Footnotes: F3

REGN transaction

Common Stock

Sale

Transaction value: -$3,105,308
Shares: -3,203
Change %: -34%
Price: $969.50
Shares after: 6,357
Date: 02 Nov 2026
Ownership: Direct
Footnotes: F4

REGN transaction

Common Stock

Sale

Transaction value: -$909,368
Shares: -937
Change %: -15%
Price: $970.51
Shares after: 5,420
Date: 02 Nov 2026
Ownership: Direct
Footnotes: F5

REGN transaction

Common Stock

Sale

Transaction value: -$195,233
Shares: -201
Change %: -3.7%
Price: $971.31
Shares after: 5,219
Date: 02 Nov 2026
Ownership: Direct
Footnotes: F6

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

REGN transaction Derivative

Non-Qualified Stock Option (right to buy)

Options Exercise

Transaction value
Shares: -7,830
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 02 Nov 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 7,830
Exercise price: $376.69
Footnotes: F7

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 7 footnotes

Footnote F1

Represents volume-weighted average price of sales of 218 shares of Company stock on November 2, 2026 at prices ranging from $966.39 to $966.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 2, 2026 at each separate price.

Footnote F2

Represents volume-weighted average price of sales of 772 shares of Company stock on November 2, 2026 at prices ranging from $967.06 to $967.75. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 2, 2026 at each separate price.

Footnote F3

Represents volume-weighted average price of sales of 2,499 shares of Company stock on November 2, 2026 at prices ranging from $968.00 to $968.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 2, 2026 at each separate price.

Footnote F4

Represents volume-weighted average price of sales of 3,203 shares of Company stock on November 2, 2026 at prices ranging from $969.01 to $969.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 2, 2026 at each separate price.

Footnote F5

Represents volume-weighted average price of sales of 937 shares of Company stock on November 2, 2026 at prices ranging from $970.00 to $970.92. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 2, 2026 at each separate price.

Footnote F6

Represents volume-weighted average price of sales of 201 shares of Company stock on November 2, 2026 at prices ranging from $971.16 to $971.62. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 2, 2026 at each separate price.

Footnote F7

The stock option vested in three equal annual installments, commencing one year after the date of grant.